On 2014 Nov 26, Matthew Katz commented:

The EORTC and SWOG trials demonstrate that radiation can improve biochemical and disease control after prostatectomy. However, it's still unclear whether it's best to wait for early 'salvage' therapy in proven PSA recurrence or to act immediately after surgery.

Future studies will be helpful for risk stratification and better patient selection. But given the low morbidity of radiotherapy after surgery, it's worthwhile discussing the pros/cons of postoperative radiation in the adjuvant setting or if the PSA begins to rise in the future.

On 2014 Nov 26, Matthew Katz commented:

The EORTC and SWOG trials demonstrate that radiation can improve biochemical and disease control after prostatectomy. However, it's still unclear whether it's best to wait for early 'salvage' therapy in proven PSA recurrence or to act immediately after surgery.

Future studies will be helpful for risk stratification and better patient selection. But given the low morbidity of radiotherapy after surgery, it's worthwhile discussing the pros/cons of postoperative radiation in the adjuvant setting or if the PSA begins to rise in the future.